Vranckx, Pascal (6603261242)Pascal (6603261242)VranckxPotpara, Tatjana (57216792589)Tatjana (57216792589)PotparaDagres, Nikolaos (7003639393)Nikolaos (7003639393)DagresHeidbuchel, Hein (7004984289)Hein (7004984289)Heidbuchel2025-06-122025-06-122016https://doi.org/10.1093/europace/euw208https://www.scopus.com/inward/record.uri?eid=2-s2.0-85012873088&doi=10.1093%2feuropace%2feuw208&partnerID=40&md5=c42e99698b89b75f780cf3dd0ac85824https://remedy.med.bg.ac.rs/handle/123456789/7596The purpose of this European Heart Rhythm Association survey was to assess the current practice concerning the use of oral anticoagulation in patients with post-operative atrial fibrillation (pre-existing or new-onset). The survey highlights the considerable heterogeneity of the type of anticoagulation, with 25% of the centres never using the non-vitamin K antagonist oral anticoagulants (NOACs) in this setting, as well the timing of oral anticoagulation initiation, the use and dosing of low-molecular-weight heparins, and the duration of anticoagulation when sinus rhythm is restored. One-third of the centres stated that they perceived that the risk of major pericardial bleeding requiring pericardiocentesis was higher when NOACs were used compared with vitamin K antagonists. Overall, the responding centres estimated the incidence of major pericardial haemorrhage to be 2.4%. More data are needed to inform practice guidelines in this field. © 2016 Published on behalf of the European Society of Cardiology. All rights reserved.AnticoagulationEHRA surveyEP wireGuidelinesHaemopericardioumNOACsNon-vitamin K antagonists oral anticoagulantsPost-operative atrial fibrillationStroke preventionWarfarin